

# FDA Complete Response Letter Analysis:

---

How 51 Companies Turned Failure into Success

## Table of Contents

About the Author

Executive Summary

Part 1: Deficiencies Cited in CRLs

Chemistry, Manufacturing and Controls

Labeling

Clinical

Quality

Regulatory

Nonclinical Deficiencies

Part 2: Lessons Learned

Part 3: CRLs and Time to Market

Appendices